Clinical trial

A Multi-Centre 12 Month Parallel-Group Randomized Control Trial of BNT162b2 Versus mRNA( Messenger Ribonucleic Acid) -1273 COVID-19 Vaccine Boosters in Chronic Kidney Disease and Dialysis Patients With Poor Humoral Response Following COVID-19 ( Corona Virus Disease of 2019)Vaccination

Name
3750
Description
This study is a 12-month, four-arm parallel-group randomized control trial of Pfizer-BioNTech versus MODERNA COVID-19 (Corona Virus disease 2019)vaccine boosters in chronic kidney disease and dialysis patients with poor humoral response following COVID-19 vaccination, in collaboration with 5 dialysis centers in Ontario and British Columbia, Canada . Patients will be randomized to MODERNA or Pfizer-BioNTech COVID-19 vaccine, they may have received either MODERNA or Pfizer-BioNTech COVID-19 vaccine for their initial two doses of vaccine, and will be stratified by their initial vaccine type (MODERNA or Pfizer-BioNTech ) prior to randomization, which will result in four study groups.
Trial arms
Trial start
2021-09-30
Estimated PCD
2022-05-11
Trial end
2022-11-15
Status
Terminated
Phase
Early phase I
Treatment
Pfizer-BioNTech COVID-19 Vaccine
This arm receives Pfizer-BioNTech COVID-19 Vaccine
Arms:
Patients who received two doses MODERNA vaccine, Arm 2, Patients who received two doses Pfizer-BioNTech vaccine, Arm 1
Other names:
BNT162b2 mRNA COVID-19 Vaccine
MODERNA SARS-CoV-2 Vaccine
This arm receives MODERNA SARS-CoV-2 Vaccine
Arms:
Patients who received two doses MODERNA vaccine, Arm 4, Patients who received two doses Pfizer-BioNTech vaccine ,Arm 3
Other names:
mRNA-1273 SARS-CoV-2 Vaccine
Size
268
Primary endpoint
Serum Level of Anti-RBD ( Anti Receptor Binding Domain )
One month
Eligibility criteria
Inclusion Criteria: * Patients with Chronic Kidney Disease (CKD)stage 3b-5 defined as an eGFR( estimated glomerular filtration rate ) of less than 45ml/min/1.73m2 or less will be eligible. Stage 5 CKD will include patients receiving in-center hemodialysis, home dialysis (home hemodialysis or peritoneal dialysis), vaccinated with two doses of the COVID-19 vaccine will be eligible for a third dose to be given 2-12 months following the second dose. * Age ≥18 at the time of study enrolment Exclusion Criteria: * Patients not vaccinated against COVID-19 vaccination. * Patients who received heterologous first two doses of vaccine * Patients with a severe allergic reaction to prior COVID-19 vaccination or any of the ingredients. * New COVID-19 infection
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 268, 'type': 'ACTUAL'}}
Updated at
2023-05-06

1 organization

2 products

2 indications

Indication
COVID-19